# Early phase 1 leukemia trials recruiting: 37 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials in early phase 1 for leukemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 leukemia trials: 37 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/leukemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 37
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 18, 2026 | NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) | Sponsor not shown (see the record) | Early phase 1 | Recruiting | AML (Acute Myeloid Leukemia), Multiple Myeloma Refractory | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771803) |
| July 10, 2026 | NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia | Zhujiang Hospital | Early phase 1 | Not yet recruiting | Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696481) |
| June 30, 2026 | NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With... | Grit Biotechnology | Early phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia (AML) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676006) |
| February 24, 2026 | NCT07429461 | Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia | Zhejiang University | Early phase 1 | Recruiting | B-Cell Acute Lymphoblastic Leukemia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429461) |
| February 24, 2026 | NCT07428707 | Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib | National Heart, Lung, and Blood Institute (NHLBI) | Early phase 1 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07428707) |
| October 3, 2025 | NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell... | Grit Biotechnology | Early phase 1 | Recruiting | B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL)... | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205315) |
| October 1, 2025 | NCT07201727 | CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | AML - Acute Myeloid Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201727) |
| September 22, 2025 | NCT07185490 | IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Not yet recruiting | Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07185490) |
| August 27, 2025 | NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | Zhejiang University | Early phase 1 | Recruiting | Acute Myeloid Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144020) |
| August 17, 2025 | NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Recruiting | AML (Acute Myelogenous Leukemia), AML | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126782) |
| July 25, 2025 | NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | Anhui Provincial Hospital | Early phase 1 | Recruiting | Multiple Myeloma (MM), Plasma Cell Leukemia (PCL), AL Amyloidosis (AL) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085559) |
| July 17, 2025 | NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Early phase 1 | Recruiting | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07071155) |
| July 11, 2025 | NCT07059975 | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | Baylor College of Medicine | Early phase 1 | Recruiting | Acute Myeloid Leukemia, Pediatric AML | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07059975) |
| May 23, 2025 | NCT06988059 | A Study of CT0596 in Plasma Cell Leukemia | Institute of Hematology & Blood Diseases Hospital, China | Early phase 1 | Recruiting | Plasma Cell Leukemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06988059) |
| May 20, 2025 | NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | Shanghai Jiao Tong University School of Medicine | Early phase 1 | Recruiting | Acute Myeloid Leukemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980155) |
| March 24, 2025 | NCT06890494 | Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia | Beijing GoBroad Hospital | Early phase 1 | Recruiting | Leukemia | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890494) |
| January 22, 2025 | NCT06786299 | Clinical Study on the Safety and Efficacy of Autologous CD84 Chimeric Antigen Receptor T-Cell Therapy for Adult Relapsed/Refractory Acute... | First Affiliated Hospital of Zhejiang University | Early phase 1 | Not yet recruiting | Relapsed/Refractory Acute Myeloid Leukemia(AML) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06786299) |
| January 7, 2025 | NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | Zhejiang University | Early phase 1 | Recruiting | Acute Myeloid Leukemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06762132) |
| January 6, 2025 | NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute... | Hrain Biotechnology Co., Ltd. | Early phase 1 | Recruiting | Acute Myeloid Leukemia (AML) | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06760260) |
| January 3, 2025 | NCT06756321 | A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy | Affiliated Hospital of Nantong University | Early phase 1 | Recruiting | Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06756321) |
| December 12, 2024 | NCT06730256 | A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia | The First Affiliated Hospital of Soochow University | Early phase 1 | Recruiting | Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06730256) |
| December 5, 2024 | NCT06718270 | a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06718270) |
| November 22, 2024 | NCT06702098 | Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia | Guangzhou Ruixin Biotechnological Co., LTD | Early phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702098) |
| October 23, 2024 | NCT06654206 | Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia Patients | University of Salamanca | Early phase 1 | Not yet recruiting | Chronic Lymphocytic Leukemia, Exercise | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06654206) |
| October 16, 2024 | NCT06643221 | Exercise as an Immune Adjuvant for Allogeneic Cell Therapies | University of Arizona | Early phase 1 | Recruiting | Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06643221) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Zhejiang University | 5 |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| Hrain Biotechnology Co., Ltd. | 2 |
| The First Affiliated Hospital of Soochow University | 2 |
| [Grit Biotechnology](https://specstream.ai/data/clinical-trials/company/grit-biotechnology) | 2 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Shanghai Changzheng Hospital | 1 |
| New York Medical College | 1 |
| Children's Hospital of Philadelphia | 1 |
| University of Arizona | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Anhui Provincial Hospital | 1 |
| Zhujiang Hospital | 1 |
| Beijing GoBroad Hospital | 1 |
| University of Salamanca | 1 |
| Nationwide Children's Hospital | 1 |
| Guangzhou Ruixin Biotechnological Co., LTD | 1 |
| Peking University People's Hospital | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| Baylor College of Medicine | 1 |
| Affiliated Hospital of Nantong University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 24 |
| United States | 10 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [German restaurants in the United States](https://specstream.ai/data/businesses/german-restaurants/united-states)
- [Livestock feed and supply stores in the United States](https://specstream.ai/data/businesses/livestock-feed-and-supply-stores/united-states)
- [Pipe suppliers in the United States](https://specstream.ai/data/businesses/pipe-suppliers/united-states)
- [Spices wholesalers in the United States](https://specstream.ai/data/businesses/spices-wholesalers/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
